Overview of Castrate-Resistant Prostate Cancer (CRPC)
An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer.
EP: 1.Incidence and Risk Factors of Prostate Cancer
EP: 2.Presentation and Diagnosis of Prostate Cancer
EP: 3.Screening and Diagnosis of Prostate Cancer
EP: 4.Prostate Cancer Prognosis and Risk Stratification
EP: 5.Differences in the Treatment of Patients with Prostate Cancer
EP: 6.Prostate Cancer: Treatment Decision-Making and the Role of Guidelines
EP: 7.Informing Prostate Cancer Treatment Decisions with Clinical Trials and Real-World Evidence
EP: 8.Systemic Therapy for Prostate Cancer
EP: 9.Androgen Deprivation Therapy for Prostate Cancer
EP: 10.Metastatic Hormone-Sensitive Prostate Cancer Treatment Options
EP: 11.Overview of Castrate-Resistant Prostate Cancer (CRPC)
EP: 12.Treatment Options for Nonmetastatic CRPC
EP: 13.Treatment Approach for Patients With Metastatic CRPC
EP: 14.The Role of Combination Therapy in mCRPC
EP: 15.Improving Clinical Trials in Prostate Cancer
EP: 16.Educating Patients and Caregivers About Prostate Cancer
EP: 17.Advice for Patients With Prostate Cancer
This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.
Dr Rashid K. Sayyid defines castrate-resistant prostate cancer as cancer cells continuing to grow despite testosterone suppression below castration levels. He states cells can become resistant to hormone therapy over time.
Castrate resistance is defined as prostate-specific antigen (PSA) increasing 25% over several weeks to an absolute value above 2 ng/mL, along with testosterone levels not being fully suppressed. Dr Sayyid notes castrate-resistant prostate cancer comprises both non-metastatic and metastatic disease, with distinction based on CT and bone scan versus PET imaging.
In summary, Dr Rashid K. Sayyid covers the definition of castrate-resistant prostate cancer, how it develops resistance to hormone therapy, diagnostic criteria involving rising PSA with testosterone not fully suppressed, and how it is categorized into non-metastatic and metastatic disease based on CT, bone scan and PET imaging findings.
*Video synopsis is AI-generated and reviewed by CURE editorial staff.
Dickey Betts Died, ‘Shopaholic’ Author Announces Cancer Diagnosis and More
April 19th 2024From the Allman Brothers Band’s singer Dickey Betts dying after a cancer diagnosis to the “Shopaholic” author announcing her glioblastoma diagnosis, here’s what is happening in the cancer space this week.
Read More
